Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.

about

Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma.Monoclonal antibodies against cutaneous T-cell lymphomas.

P2860

Q48248214-8505DD97-AF4A-431F-B486-01A44D8FB1A1 Q51803389-FD7060F8-7C0F-4AD2-BB40-99C9A2ADB4F0

P2860

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.

Item

http://www.wikidata.org/entity/Q46006814

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Results from a Phase I/II Open ...... ory Cutaneous T-cell Lymphoma.

@en

Results from a Phase I/II Open ...... ory Cutaneous T-cell Lymphoma.

@nl

type

Item

label

Results from a Phase I/II Open ...... ory Cutaneous T-cell Lymphoma.

@en

Results from a Phase I/II Open ...... ory Cutaneous T-cell Lymphoma.

@nl

prefLabel

Results from a Phase I/II Open ...... ory Cutaneous T-cell Lymphoma.

@en

Results from a Phase I/II Open ...... ory Cutaneous T-cell Lymphoma.

@nl

P1476

Results from a Phase I/II Open ...... ory Cutaneous T-cell Lymphoma.

@en

P2093

Madeleine Duvic

http://www.w3.org/2001/XMLSchema#string

Steven M Horwitz

http://www.w3.org/2001/XMLSchema#string

Youn H Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Methotrexate and Pralatrexate

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

Mycosis fungoides: pathophysiology and emerging therapies.

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.

Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

P304

3552-3556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-16-2064

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pier Luigi Zinzani

P577

2017-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28167509

http://www.w3.org/2001/XMLSchema#string

P932

5511551

http://www.w3.org/2001/XMLSchema#string

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.

about

P2860

P2860

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932